Delivery of Anticancer Drugs Using a Supramolecular Complex to Cancer Tissues Having High Interstitial Fluid Pressure

Arima Hidetoshi

doi:10.1248/yakushi.19-00218-2

Bibliographic Information

Other Title

超分子複合体を用いた間質圧の高い腫瘍への抗がん剤デリバリー
Symposium Review 超分子複合体を用いた間質圧の高い腫瘍への抗がん剤デリバリー
Symposium Review チョウブンシフクゴウタイオモチイタカンシツアツノタカイシュヨウエノコウガンザイデリバリー

Search this article

Abstract

<p>Pancreatic cancer is the fourth-leading cause of death from cancer in Japan, after lung, colorectal, and stomach cancers and has the lowest survival among these tumors, because of not only no symptoms, no screening tool and no biomarkers but also high rates of recurrence and metastasis. In addition, pancreatic cancer has excessive stroma which serves as a severe biological barrier for anticancer drug delivery and successful treatment. Therefore, there are many challenges for drug delivery systems for the treatment of pancreatic cancer. Recently, we developed self-assembly PEGylation retaining activity (SPRA) technology, which comprises a reversible pegylated protein complex without loss of bioactivity. SPRA technology is based on a host-guest interaction between PEGylated β-cyclodextrin and adamantane-appended protein. In this review, first pancreatic cancer is introduced, second, principle drug delivery systems for the treatment of pancreatic cancer are described, and third the concept of SPRA technology as well as examples of SPRA proteins, especially focusing on the potential of SPRA-bromelain for treatment of pancreatic cancer, are introduced.</p>

Journal

YAKUGAKU ZASSHI

YAKUGAKU ZASSHI 140 (5), 617-624, 2020-05-01

The Pharmaceutical Society of Japan

Keywords

Details 詳細情報について

Export